Latest research on Rituxan

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

Rituxan side effects

Interestingly, the HC signal peptide 7 (H7) resulted in significantly increased secretion for Avastin, Remicade, Rituxan and Humira. [source, 2015]
In the era of MabThera, the cure rate for DLBCL has increased significantly beyond that for the standard therapeutic strategy, but conventional treatment is still ineffective in approximately 30% of patients [1]; the reasons for this lack of activity in certain patients require investigation. [source, 2015]
All the 135 patients received the first-line treatment regimen—R-CHOP/CHOP/CHOP-like, 28 patients abandoned Mab Thera because of individual reason (economical reason mostly) (20 in HBV-free group and 8 in HBV infection group); 100 patients received MabThera (74.1%), and 16 underwent radiotherapy. [source, 2015]
MabThera increases the risk of HBV reactivation, depletion of B cells in the circulation is the main mechanism, and this may induce immune disorder toward HBV. [source, 2015]
Certainly, there were patients with a high HBV viral load, and their therapy was slightly delayed compared with the other patients; therapy began once the HBV DNA level decreased to 105, and these patients all regularly received MabThera for at least 3 cycles. [source, 2015]
Therefore, the use of MabThera increased the overall therapeutic effect in patients with DLBCL [1,7–8]. [source, 2015]
Thus, Rituxan could enhance the cytotoxic sensitivity of lymphoma cells, and synergize with chemotherapy without a clinically significant increase in toxicity (15). [source, 2015]
The use of newer targeted therapies with poor CNS penetration such as trastuzumab (Herceptin used for her2/neu positive cancers) and rituximab (Rituxan used for B-cell malignancies) is another factor that contributes to an increased incidence of LM.[9131168212] [source, 2013]
Rituxan causes a profound depletion of circulating B cells, but presumably does not deplete plasma cells, which do not have CD20 on their surface. [source, 2011]
When Rituxan attacks or cross links to CD20 there is an increase in intracellular Ca++ and further phosphorylation of the inner chain of CD20. [source, 2010]